Compare VHC & ZTEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VHC | ZTEK |
|---|---|---|
| Founded | 2005 | 2008 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Major Chemicals |
| Sector | Miscellaneous | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.2M | 78.2M |
| IPO Year | 1999 | N/A |
| Metric | VHC | ZTEK |
|---|---|---|
| Price | $20.41 | $0.76 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 32.5K | ★ 97.7K |
| Earning Date | 03-16-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $106,000.00 | ★ $657,134.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 2020.00 | ★ 2225.73 |
| 52 Week Low | $6.60 | $0.62 |
| 52 Week High | $29.00 | $1.84 |
| Indicator | VHC | ZTEK |
|---|---|---|
| Relative Strength Index (RSI) | 50.05 | 45.49 |
| Support Level | $19.27 | $0.75 |
| Resistance Level | $22.67 | $0.89 |
| Average True Range (ATR) | 1.56 | 0.09 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 40.62 | 1.47 |
VirnetX Holding Corp is engaged in the business of commercializing a portfolio of patents. It is an Internet security software and technology company with patented technology for secure communications. The company's software and technology solutions, including its Secure Domain Name Registry and Technology, VirnetX One, War Room, VirnetX Matrix, and GABRIEL Connection Technology, are designed to be device and location-independent, and enable a secure real-time communication environment for all types of enterprise applications, services and critical infrastructures.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.